Sole Source for OSPHL: Sequencing platform & annual service agreements

The Oregon State Public Health Laboratory (OSPHL) is pursuing a sole source procurement for advanced sequencing technology and related services. This opportunity focuses on acquiring Illumina MiSeq and MiniSeq sequencing platforms, along with comprehensive annual service agreements and supporting infrastructure. The procurement includes annual BaseSpace Sequence Hub subscriptions, necessary reagents, test kits, and consumables required to perform specialized testing procedures. The contract opportunity was posted on October 20, 2025, with proposals due by October 27, 2025, indicating a relatively tight submission timeline. While specific evaluation criteria are not explicitly detailed in the provided documentation, the sole source nature suggests a targeted procurement with predetermined vendor specifications. The primary objective appears to be enhancing the laboratory's genomic and diagnostic testing capabilities through advanced sequencing technologies.

As a sole source procurement, this opportunity likely has restricted competitive bidding and may be limited to specific vendor qualifications. The contract does not explicitly mention set-aside designations for disadvantaged enterprises or small businesses. Given the specialized nature of the sequencing platforms and associated technologies, potential respondents would need extensive expertise in genomic testing equipment and laboratory informatics. While precise budget ranges are not specified, advanced sequencing platforms and comprehensive service agreements typically represent significant capital investments, potentially ranging from several hundred thousand to over a million dollars. The integration requirements will likely necessitate compatibility with existing OSPHL laboratory information systems and current technological infrastructure. Vendors must demonstrate comprehensive technical support, ongoing service capabilities, and the ability to provide specialized reagents and consumables compatible with the specified Illumina sequencing platforms.